Charles River Laboratories International, Inc. $CRL Shares Acquired by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp increased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 15.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,529 shares of the medical research company’s stock after buying an additional 8,000 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Charles River Laboratories International were worth $11,675,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Tema Etfs LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $26,000. Rothschild Investment LLC raised its position in shares of Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after buying an additional 84 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $42,000. Sfam LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $43,000. Finally, Activest Wealth Management raised its position in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after buying an additional 218 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $188.74 on Tuesday. Charles River Laboratories International, Inc. has a 1 year low of $143.06 and a 1 year high of $228.88. The firm has a 50 day moving average price of $173.80 and a 200 day moving average price of $182.57. The company has a market cap of $9.09 billion, a price-to-earnings ratio of -50.20, a PEG ratio of 2.14 and a beta of 1.46. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. During the same period in the previous year, the firm earned $2.34 earnings per share. Charles River Laboratories International’s revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current year.

Analyst Ratings Changes

CRL has been the subject of a number of recent analyst reports. Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. JPMorgan Chase & Co. lowered their target price on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Monday, April 13th. Barclays boosted their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. UBS Group boosted their target price on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Finally, Mizuho set a $192.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average target price of $208.50.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.